Treatment of HIV Gilead Biktarvy is safe and effective in the age group of 65-year-old comorbidity
-
Last Update: 2020-07-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Biktarvy was approved by the U.SFDA in February 2018 for the drug, which is intended as a complete treatment for HIV-1 infections in children and adults weighing at least 25 kg, including: (1) first-line treatment: for people with no history of antiretroviral therapy;in China, Biktarvy (Pytovy ®) was approved by Hong Kong in October 2018 and mainland China in August 2019On the mainland, the drug is suitable for: as a complete treatment for HIV-1 infection in adults, and the patient currently and in the past has no evidence of viral resistance to the combination enzyme inhibitor stake, enqualamine or noofovirOriginal source: New Findings on Gilead's Biktarvy ® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older AdultsOriginal title: New HIV Drugs! Gilead Biktarvy (Pytovi ®) is safe and effective in the age group of 65-year-old comorbidities and is listed in China!
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
